{
  "source": "PA-Notification-Zelboraf.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1119-13\nProgram Prior Authorization/Notification\nMedication Zelboraf® (vemurafenib)\nP&T Approval Date 8/2012, 7/2013, 5/2014, 5/2015, 5/2016, 3/2017, 3/2018, 3/2019, 3/2020,\n3/2021, 3/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nZelboraf (vemurafenib) is a kinase inhibitor indicated for the treatment of patients with\nunresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-\napproved test. It is also indicated for the treatment of patients with Erdheim-Chester Disease\nwith BRAF V600 mutation. Zelboraf is not recommended for use in patients with wild-type\nBRAF melanoma.1\nThe National Cancer Comprehensive Network (NCCN) guideline recommends use of Zelboraf\nin combination with Cotellic (cobimetinib) for treatment of central nervous system (CNS) cancer\nand metastatic or unresectable melanoma with a BRAF V600 mutation (or as a single agent if\nBRAF/MEK inhibitor combination therapy is contraindicated). Zelboraf is also recommended\nfor the treatment of hairy cell leukemia, non-small cell lung cancer (NSCLC), Langerhans cell\nhistiocytosis (LCH), and follicular, Hürthle cell, and papillary thyroid carcinomas with a BRAF\nmutation.2\nInformation on FDA-approved tests for the detection of BRAF V600 mutations in melanoma\nmay be found at: http://www.fda.gov/CompanionDiagnostics.1\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Zelboraf will be approved based on the f",
    "andates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Zelboraf will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Melanoma\n© 2025 UnitedHealthcare Services, Inc.\n1\n1. Initial Authorization\na. Zelboraf will be approved based on both of the following criteria:\n(1) One of the following diagnoses:\n(a) Unresectable melanoma\n(b) Metastatic melanoma\n-AND-\n(2) Patient is positive for BRAFV600 mutation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zelboraf will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Zelboraf therapy\nAuthorization will be issued for 12 months.\nC. Central Nervous System (CNS) Cancers\n1. Initial Authorization\na. Zelboraf will be approved based on all of the following criteria:\n(1) One of the following:\n(a) Both of the following:\ni. Patient has metastatic brain lesions\n-AND-\nii. Zelboraf is active against primary tumor (melanoma)\n-OR-\n(b) Both of the following:\ni. Diagnosis of Glioma\n-AND-\nii. One of the following:\n© 2025 UnitedHealthcare Services, Inc.\n2\n• Incomplete resection, biopsy, or surgically inaccessible location\n• Disease is recurrent or progressive\n-AND-\n(2) Cancer is positive for BRAF V600E mutation\n-AND-\n(3) Used in combination with Cotellic (cobimetinib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zelboraf will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Zelboraf therapy\nAuthorization will be issued for 12 months.\nD. Hairy Cell Leukemia\n1. Initial Authorization\na. Zelboraf will be approved based on the following diagnosis:\n(1) Diagnosis of hairy cell leukemia\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zelboraf will be approved based on the following crite",
    "approved based on the following diagnosis:\n(1) Diagnosis of hairy cell leukemia\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zelboraf will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Zelboraf therapy\nAuthorization will be issued for 12 months.\nE. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Zelboraf will be approved based on all of the following:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n-AND-\n(2) Disease is one of the following:\n© 2025 UnitedHealthcare Services, Inc.\n3\n(a) Metastatic\n(b) Advanced\n(c) Recurrent\n-AND-\n(3) Cancer is positive for BRAF V600E mutation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zelboraf will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Zelboraf therapy\nAuthorization will be issued for 12 months.\nF. Histiocytic Neoplasms\n1. Initial Authorization\na. Zelboraf will be approved based on both of the following:\n(1) Diagnosis of one of the following:\n(a) Erdheim-Chester Disease\n(b) Langerhans Cell Histiocytosis\n-AND-\n(2) Cancer is positive for BRAF V600 mutation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zelboraf will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Zelboraf therapy\nAuthorization will be issued for 12 months.\nG. Thyroid Cancer\n1. Initial Authorization\na. Zelboraf will be approved based on all of the following:\n© 2025 UnitedHealthcare Services, Inc.\n4\n(1) Diagnosis of one of the following:\n(a) Follicular carcinoma\n(b) Oncocytic carcinoma\n(c) Papillary carcinoma\n-AND-\n(2) One of the following:\n(a) Unresectable locoregional recurrent disease\n(b) Metastatic disease\n(c) Persistent disease\n-AND-\n(3) One of the following:\n(a) Patient has symptomatic disease\n(b) Patient has progressive disease\n-AND-\n(4) Disease is refractory to radioactive iodine\n",
    "Metastatic disease\n(c) Persistent disease\n-AND-\n(3) One of the following:\n(a) Patient has symptomatic disease\n(b) Patient has progressive disease\n-AND-\n(4) Disease is refractory to radioactive iodine\n-AND-\n(5) Cancer is positive for BRAF V600 mutation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zelboraf will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Zelboraf therapy\nAuthorization will be issued for 12 months.\nH. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n© 2025 UnitedHealthcare Services, Inc.\n5\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Zelboraf [package insert]. South San Francisco, CA: Genentech, Inc.; May 2020.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed February 10, 2025.\nProgram Prior Authorization/Notification - Zelboraf (vemurafenib)\nChange Control\n5/2014 Annual review with no change to coverage.\n5/2015 Annual review. Added criteria for CNS cancer and NSCLC. Updated\nbackground and references. Increased authorization to 12 months.\n5/2016 Annual review. Removed incompletely resected or recurrent from\nmelanoma. Updated background and references.\n3/2017 Annual revi",
    "d\nbackground and references. Increased authorization to 12 months.\n5/2016 Annual review. Removed incompletely resected or recurrent from\nmelanoma. Updated background and references.\n3/2017 Annual review. Changed Member to Patient in criterion. Updated\nreferences.\n3/2018 Annual review. Updated background and criteria to include new indication\nfor Erdheim-Chester Disease and NCCN recommended off-label use in\nBRAF mutation positive colon, rectal, and thyroid cancer. Updated\nreferences.\n3/2019 Annual review. Updated criteria for NCCN recommended use in CNS\ncancer. Updated background and references.\n3/2020 Annual review. Added general NCCN recommendations for use criteria.\nUpdated references.\n3/2021 Annual review. Updated coverage criteria for CNS cancer per NCCN\nrecommendations. Removed coverage criteria for colon and rectal cancer.\nThese recommendations were not included in current version of NCCN\nguidelines for colon or rectal cancer. Updated references.\n3/2022 Annual review. Updated background and coverage criteria for Langerhans\ncell histiocytosis per NCCN recommendations.\n3/2023 Annual review. Updated background and CNS coverage criteria per NCCN\nrecommendations. Updated reference. Added state mandate footnote.\n3/2024 Annual review. Updated nomenclature under Thyroid carcinoma from\nHurthle cell to oncocytic with no change to clinical intent. Updated\nreference.\n3/2025 Annual review with no change to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n6"
  ]
}